Menu
Search
|

Menu

Close
X

Synlogic Inc SYBX.OQ (NASDAQ Stock Exchange Global Market)

11.00 USD
-0.07 (-0.63%)
As of Jul 20
chart
Previous Close 11.07
Open 11.00
Volume 42,326
3m Avg Volume 37,462
Today’s High 11.07
Today’s Low 10.73
52 Week High 23.00
52 Week Low 8.73
Shares Outstanding (mil) 16.28
Market Capitalization (mil) 291.62
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.554
FY17
-3.573
FY16
-9.900
FY15
-19.546
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
8.00
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-47.28
14.61
Return on Equity (TTM)
vs sector
-47.28
16.34

EXECUTIVE LEADERSHIP

Michael Powell
Chairman of the Board, Since 2012
Salary: --
Bonus: --
Aoife Brennan
Interim President and Chief Executive Officer, Chief Medical Officer, Since 2018
Salary: --
Bonus: --
Todd Shegog
Chief Financial Officer, Secretary, Since 2017
Salary: --
Bonus: --
Andrew Gengos
Chief Operating Officer - Head of Corporate Development, Since 2017
Salary: --
Bonus: --
Paul Miller
Chief Scientific Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

301 Binney St Ste 402
CAMBRIDGE   MA   02142-1030

Phone: +1617.4019975

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

SPONSORED STORIES